




Casgevy (exagamglogene autotemcel) Gene Therapy
One-time gene therapy treatment
(+4)
Casgevy represents a monumental leap as the first FDA-approved CRISPR-based gene-editing therapy. It offers a functional cure for severe genetic blood disorders, transforming the lives of patients with sickle cell disease and beta-thalassemia.

















































